Basophil FceRI expression-A management tool in anti-IgE treatment of allergic asthma.

Autor: Rubak SLM; Department of Child and Adolescent Health, Center of Pediatric Pulmonology and Allergology, Aarhus University Hospital, Aarhus, Denmark., Bonne NL; Department of Child and Adolescent Health, Aarhus University Hospital, Aarhus, Denmark., Hjerrild BE; Department of Child and Adolescent Health, Center of Pediatric Pulmonology and Allergology, Aarhus University Hospital, Aarhus, Denmark., Hoffmann HJ; Department of Clinical Medicine, Department of Clinical Immunology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: Pediatric pulmonology [Pediatr Pulmonol] 2024 Dec; Vol. 59 (12), pp. 3355-3363. Date of Electronic Publication: 2024 Aug 07.
DOI: 10.1002/ppul.27206
Abstrakt: Background: Immune-based therapy targeting immunoglobulin E (IgE), anti-IgE treatment, has emerged as an adjunct treatment for children with severe allergic asthma. After start of anti-IgE treatment, an effect of the treatment cannot be monitored by Total-IgE, because current methods measure both bound and free IgE molecules. Basophil activation test may be very useful for monitoring anti-IgE treatment efficacy. The objective of this paper is to evaluate if basophil activation test is applicable in regulating the anti-IgE treatment.
Methods: A case series of 20 children with IgE-mediated severe allergic asthma were treated according to guidelines with anti-IgE (Omalizumab). Blood samples were drawn for total IgE, specific IgE, number of IgE receptors (FcεRI) and basophil sensitivity were measured at baseline before anti-IgE treatment and 4 months after initiation of anti-IgE treatment.
Results: A total of 19 out of 20 children had statistically significant and clinically relevant effects of anti-IgE treatment on symptom score, lung function and medication. All 20 children had a significant reduction in basophil allergen sensitivity and the number of IgE receptors (FcεRI) on blood basophils. Anti-IgE treatment was found to be well controlled by measuring basophil allergen sensitivity and FceRI density on blood basophils.
Conclusion: This cohort study demonstrates a promising method, measuring basophil allergen sensitivity and in particular blood basophil FceRI density, concerning the monitoring of anti-IgE treatment in different clinical situations. There are no randomized controlled trials evaluating this method in clinical settings.
(© 2024 The Author(s). Pediatric Pulmonology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: